摘要目的 探讨芪白平肺胶囊对慢性阻塞性肺疾病(COPD)痰瘀阻肺证模型大鼠右心肥厚的影响.方法 将60只大鼠按照随机数字表,随机分为正常对照组、模型组、川芎嗪组、硝苯地甲组、芪白平肺胶囊高、芪白平肺胶囊低剂量组,每组各10只,采用复合因素造模方法制作COPD痰瘀阻肺证大鼠模型,造模的同时分别给与芪白平肺胶囊、川芎嗪、硝苯地平,观察各药对右心肥厚指标的影响.结果 芪白平肺胶囊高剂量组有心肥厚指标与正常对照组比较,无统计学意义(P＞0.05);硝苯地平组右心肥厚指标与模型组比较,无统计学意义(P＞0.05);川芎嗪组、芪白平肺胶囊低剂量组右心肥厚指标较模型组比较,有统计学意义(P＜0.01);川芎嗪组、芪白平肺胶囊低剂量组较正常对照组有显著差异(P＜0.01、P＜0.05).结论 高剂量芪白平肺胶囊可有效防治COPD痰瘀阻肺证模型大鼠右心肥厚的产生.川芎嗪对防治有心肥厚有一定疗效,但不及高剂量芪白平肺胶囊.

abstractsObjectlve To explore the effect of Qibai Pingfei capsule on the right ventricular hypertrophy index (RVHI)of rats with phlegm and blood stasis of COPD.Methods 60 rats were randomly divided into 6 groups,a control group,a model group,a Ligustrazine group,a Nifedipine group,a high dose Qibai Pingfei capsule group and a low dose Qibai Pingfei capsule group.Composite factors method was adopted to establish phlegm and blood stasis COPD rat model.At the same time of modeling.Qibai Pingfei capsule,Ligustrazine,Nifedipine were also given to these rats.Observed the changes of RVHI in each group.Results RVHI did not show statistic difierence between high dose of the Qibai Pingfei capsule group and the control group(P＞0.05).and between the Nifedipine group and the model group(P＞0.05).RVHI manifested significant diffbrencc between the Ligustrazine group and the low dose Qibai Pingfei capsule group(P＜0.01),and between the Ligustrazine group and the control group(P＜0.01).Conclusion High dose Qibai Pingfei capsule can effectively prevent the right ventricular hypertrophy of model rats with the phlegm and blood stasis of COPD.Ligustrazine has certain effects but not as good as high dose Qibai Pingfei capsule.Nifedipine can not prevent the right ventricular hypertrophy of model rats.